Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 21

Results For "ADA"

1060 News Found

Bristol Myers Squibb launches AI-powered ‘Mosaic’ hub in Mumbai
News | December 17, 2025

Bristol Myers Squibb launches AI-powered ‘Mosaic’ hub in Mumbai

India plays a critical role in Bristol Myers Squibb’s global strategy


Pharma overhaul: EMA hails “Once-in-a-Generation” reform
Policy | December 16, 2025

Pharma overhaul: EMA hails “Once-in-a-Generation” reform

The reform is set to modernise how medicines are developed, authorised, and made available across the EU


Biocon Biologics strikes deal to sell its version of the eye drug Aflibercept worldwide
News | December 14, 2025

Biocon Biologics strikes deal to sell its version of the eye drug Aflibercept worldwide

All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed


Neurizon’s ALS drug regimen cleared for launch in Healey platform trial
Clinical Trials | December 12, 2025

Neurizon’s ALS drug regimen cleared for launch in Healey platform trial

The Healey ALS Platform Trial is a multicenter, double-blind, placebo-controlled


Roche bags CE Mark for automated mass spectrometry antibiotics monitoring
News | December 12, 2025

Roche bags CE Mark for automated mass spectrometry antibiotics monitoring

The cobas Mass Spec solution Ionify reagent portfolio now covers therapeutic drug monitoring for immunosuppressants and antibiotics


Bristol Myers Squibb unveils breakthrough Lymphoma data
News | December 11, 2025

Bristol Myers Squibb unveils breakthrough Lymphoma data

Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas


Roche’s Columvi combo doubles survival in hard-to-treat lymphoma
Clinical Trials | December 09, 2025

Roche’s Columvi combo doubles survival in hard-to-treat lymphoma

Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma


Freenome strikes SPAC deal to go public in 2026
Biotech | December 08, 2025

Freenome strikes SPAC deal to go public in 2026

Freenome expects the combined company to receive approximately $330 million in proceeds at closing


Eurofins launches first GMP PFAS testing solution for medical devices
Medical Device | December 05, 2025

Eurofins launches first GMP PFAS testing solution for medical devices

Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates